EUVIMED · CrossrefZeitschrift
Biologics in Therapy
ISSN 2190-9164 · Springer Science and Business Media LLC
Neueste Artikel
Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe’s disease
Letter from the Editor
Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data
Rotarix in Japan: Expectations and Concerns
New Frontiers in Subcutaneous Immunoglobulin Treatment
Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency
Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases
Erratum to: Human Plasma-Derived, Nanofiltered C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting From C1-Inhibitor Deficiency
Axitinib in Metastatic Renal Cell Carcinoma
Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab
Cost-Effectiveness of Infliximab for the Treatment of Acute Exacerbations of Ulcerative Colitis in the Netherlands
Brentuximab Vedotin in CD30+ Lymphomas
Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept
The Role of Biological and Small Molecule Therapy in the Management of Psoriatic Arthritis
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
Golimumab: A Novel Anti-Tumor Necrosis Factor
Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures
One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age
To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden”
Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening
Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency
Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting
Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
Publisher’s Note
EUVIMED